Indivior, leader in opioid treatment, trades near 52-week lows. Read more on INDV stock's financials, growth challenges, and ...

was abandoned in late-stage development in 2017 after five deaths in its clinical trial programme related to severely low white blood cells (agranulocytosis) and sepsis. Exscientia said it had ...

The median age of patients was 63 years, and 60% were men. Agranulocytosis and platelet counts <20 × 10 9 were observed in all patients. Consequently, all patients were unable to undergo ...

Patients can be maintained in the long term on low-dose ATD, but there is still the very small risk of agranulocytosis and, as alluded to above, relapse can still occur on stopping. Many young people ...

Advances Company’s industry-leading portfolio in mental health with addition of CAPLYTA ® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an ...

Johnson & Johnson today announced it has completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies is now part of Johnson & Johnson and will operate as a business unit ...

† Safety classification according to the US FDA pregnancy risk classification. ↓: Decrease; AVNRT: Atrioventricular nodal re-entry tachycardia; AVRT: Atrioventricular re-entry tachycardia; BP ...